Ozempic carries an FDA black box warning for thyroid C-cell tumors based on rodent carcinogenicity studies — but rodent thyroid tissue has 5 to 10 times more GLP-1 receptors in C-cells than human thyroid tissue, which makes direct extrapolation biologically unsound. Five years of human clinical trial data from the SUSTAIN and LEADER programs, covering more than 14,000 patients, have not demonstrated a statistically significant increase in medullary thyroid carcinoma in humans taking semaglutide or liraglutide.
That does not make the warning irrelevant. There are specific populations who should not take GLP-1 drugs at all, and specific monitoring steps that matter for everyone else. The problem is that most of the public conversation about this warning is either alarmist or dismissive — neither of which helps you make an informed decision about your own risk.
What the FDA Black Box Warning Actually Says
The black box warning on semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and other GLP-1 receptor agonists states that these drugs cause dose-dependent and duration-dependent thyroid C-cell tumors in male and female rats and mice at clinically relevant exposures. The FDA requires that GLP-1 drugs be contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
The key word in the warning is “relevance to humans is unknown.” The FDA did not find evidence of human thyroid C-cell tumors in the available data at the time of approval — it required the warning because preclinical carcinogenicity studies are a regulatory prerequisite, and the rodent data was positive. This is a different thing from established human risk, and the distinction is material to how you interpret what you read about it. For broader context on how semaglutide works beyond weight loss, Semaglutide Muscle Loss: How to Keep Lean Mass covers the mechanism in detail.
Why Rodent Data Does Not Translate Directly to Humans for This Specific Drug
GLP-1 receptor density in thyroid C-cells — the parafollicular cells that produce calcitonin — differs dramatically between species. Rat and mouse C-cells express GLP-1 receptors at 5 to 10 times the density of human C-cells. This means that the same circulating drug concentration produces a much stronger receptor-mediated stimulus in rodent thyroid tissue than in human thyroid tissue. The C-cell proliferation observed in rodent studies at clinical GLP-1 concentrations would require significantly higher concentrations to produce the same effect in human C-cells, if it produced any effect at all.
A 2013 analysis by Bjerre Knudsen et al., published in Endocrinology, directly compared GLP-1 receptor expression in thyroid tissue across species and found essentially no GLP-1 receptor expression in normal human thyroid C-cells using both immunohistochemistry and quantitative PCR. This does not definitively rule out an effect at supraphysiological drug concentrations or in C-cell hyperplasia states, but it substantially weakens the mechanistic basis for the rodent-to-human extrapolation.
What the Human Clinical Trial Data Shows
The LEADER trial (liraglutide, 9,340 patients, median 3.8 years) and the SUSTAIN-6 trial (semaglutide, 3,297 patients, 2 years) both pre-specified thyroid neoplasms as safety endpoints. Neither trial found a statistically significant increase in thyroid cancer incidence in the GLP-1 arm versus placebo. Calcitonin levels, a sensitive biomarker for C-cell activity, showed no clinically significant elevation in either trial population.
A 2023 real-world pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database, published in Diabetes Care, found no signal for medullary thyroid carcinoma in semaglutide users beyond the background population rate. The analysis covered approximately 1.5 million patient-years of semaglutide exposure across approved indications. Papillary thyroid carcinoma (a different and far more common thyroid cancer not driven by C-cell GLP-1 signaling) showed no elevated incidence either. The full context of how Semaglutide Muscle Loss: How to Keep Lean Mass compares to other interventions is relevant for anyone weighing these risks against benefits.
Who Should Not Take GLP-1 Drugs: The Real Contraindications
The contraindications are specific and the risk profile for people outside them is different. You should not take semaglutide, liraglutide, or any GLP-1 receptor agonist if you have a personal history of medullary thyroid carcinoma — a rare cancer of the C-cells that accounts for approximately 2 to 3% of all thyroid cancers in the United States, or roughly 900 new cases per year. You should also not take these drugs if you have Multiple Endocrine Neoplasia type 2A or 2B (MEN2), a hereditary syndrome caused by RET proto-oncogene mutations that predisposes to MTC, pheochromocytoma, and parathyroid adenomas.
Family history matters here. If a first-degree relative has been diagnosed with MTC or MEN2, genetic counseling and RET mutation testing should precede any GLP-1 prescription. This is not a common scenario — MEN2 affects approximately 1 in 35,000 people globally — but it is a genuine absolute contraindication where the animal data has at least theoretical plausibility because C-cell proliferation is already dysregulated in these patients. For people researching various Thyroid and PCOS: The Overlooked Connection, understanding which contraindications apply to which drugs is the most important starting point.
Thyroid Monitoring Recommendations: What Is Actually Evidence-Based
Routine calcitonin screening before starting GLP-1 therapy is not universally recommended by clinical guidelines, including the American Diabetes Association and the Endocrine Society. Calcitonin is produced by thyroid C-cells and is the primary tumor marker for MTC; elevated baseline calcitonin (above 50 to 100 pg/mL, depending on the assay and laboratory) warrants ultrasound evaluation and endocrinology referral before starting GLP-1 drugs.
If your personal or family history is unclear regarding MTC or MEN2, a single baseline thyroid ultrasound is a reasonable precaution that most endocrinologists support even in the absence of a guideline mandate. Annual TSH testing during GLP-1 therapy is standard of care for monitoring general thyroid function, though TSH is a measure of follicular cell function rather than C-cell activity — it will not detect early MTC. Calcitonin monitoring during therapy is not currently recommended by any major guideline absent symptoms or elevated baseline, primarily because routine monitoring would generate an enormous number of false positives given how rare MTC is.
The Lawsuit Context: What Class Action Cases Are and Are Not Saying
As of early 2026, Novo Nordisk and Eli Lilly face class action lawsuits in US federal courts alleging failure to adequately warn patients about thyroid cancer risk from GLP-1 drugs. These suits are legally significant but should not be interpreted as scientific confirmation of harm. Class action filings allege that the companies knew or should have known about risks and failed to disclose them adequately — they are based on the same animal data that generated the black box warning, not on new human evidence of causation.
The MDL (Multi-District Litigation) also includes claims around gastroparesis and other gastrointestinal injuries, which have a more direct mechanistic basis given GLP-1’s well-documented effects on gastric motility. Separating the thyroid litigation from the GI litigation matters: the gastroparesis claims rest on human physiology and documented cases; the thyroid claims rest primarily on rodent data and the precautionary logic of the black box warning. Courts adjudicate liability, not biological plausibility — a settlement or verdict in these cases would not constitute scientific evidence that semaglutide causes MTC in humans.
Calcitonin as a Tumor Marker: When Your Doctor Orders It
Calcitonin is a hormone secreted by thyroid C-cells with a physiological role in calcium homeostasis that is actually modest in adult humans (parathyroid hormone and vitamin D are far more dominant regulators). Its clinical value is almost entirely as an MTC biomarker. Normal calcitonin in healthy adults is below 5 to 10 pg/mL in women and below 10 to 20 pg/mL in men, with assay-specific reference ranges.
If a doctor orders calcitonin in the context of GLP-1 therapy evaluation, it is either a precautionary baseline (appropriate if history is unclear), a response to a thyroid nodule found on imaging (also appropriate — calcitonin is standard in the nodule workup), or it is following up on a mildly elevated previous result. Mildly elevated calcitonin below 100 pg/mL has many causes beyond MTC, including renal insufficiency, proton pump inhibitor use, hypercalcemia, and C-cell hyperplasia that does not progress to carcinoma. An elevated result requires specialist interpretation, not alarm — the positive predictive value of a calcitonin level between 20 and 100 pg/mL for MTC is below 10% in unselected populations.
Frequently Asked Questions
Does Ozempic actually cause thyroid cancer in humans?
No confirmed human causation exists as of 2026. The FDA black box warning is based on rodent studies where GLP-1 receptor density in thyroid C-cells is 5 to 10 times higher than in humans. Five years of clinical trial data from 14,000+ patients in LEADER and SUSTAIN-6, plus real-world pharmacovigilance from approximately 1.5 million patient-years, have not found a statistically significant increase in medullary thyroid carcinoma in GLP-1 users.
Who should not take Ozempic because of thyroid risk?
GLP-1 drugs are absolutely contraindicated in people with a personal history of medullary thyroid carcinoma (MTC) or a diagnosis of Multiple Endocrine Neoplasia type 2 (MEN2). If a first-degree relative has been diagnosed with MTC or MEN2, RET mutation genetic testing should precede any GLP-1 prescription. Outside these specific groups, thyroid cancer risk from GLP-1 drugs is not established in human data.
Should I get my thyroid checked before starting Ozempic?
Current clinical guidelines do not mandate routine thyroid screening before GLP-1 therapy unless you have a personal or family history of MTC or MEN2. A baseline calcitonin level is reasonable if your family history is unclear. Standard TSH testing at baseline and annually is supported by general endocrine monitoring standards regardless of GLP-1 use. If you have an existing thyroid nodule, standard workup including calcitonin should occur before starting GLP-1 therapy.
What is calcitonin and why does it matter with Ozempic?
Calcitonin is a hormone produced by thyroid C-cells and is the primary blood marker for medullary thyroid carcinoma. Normal levels are below 10 to 20 pg/mL depending on sex and assay. In the context of GLP-1 therapy, calcitonin is checked as a precautionary MTC screen in patients with unclear thyroid history or existing thyroid nodules. Mildly elevated calcitonin has multiple causes and requires specialist interpretation — it does not confirm MTC.
Do the Ozempic lawsuits prove thyroid cancer risk?
No. Lawsuits allege failure to warn based on known animal data — they do not introduce new human evidence of causation. The thyroid cancer litigation against Novo Nordisk rests on the same rodent carcinogenicity data that generated the FDA black box warning. Legal liability decisions and scientific causation determinations are separate processes; a lawsuit settlement would not constitute evidence that semaglutide causes medullary thyroid carcinoma in humans.
